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n Search of an Algorithm to
revent Acute Kidney Injury*
arold L. Dauerman, MD
urlington, Vermont
n this issue of JACC: Cardiovascular Interventions, Brown et
l. (1) present a meta-analysis of 10 trials involving com-
ined therapy with sodium bicarbonate (NaHCO3) plus
-acetylcysteine (NAC) and demonstrate a significant re-
uction in acute kidney injury (AKI) with this regimen as
ompared with other prophylactic strategies. Given that the
isk of contrast-induced AKI in high-risk patient groups
ight exceed 20% (2,3) and that AKI is associated with
onsiderable morbidity (4), a simple strategy for AKI
rophylaxis could potentially lead to significant quality im-
See page 1116
rovement across cardiovascular catheterization laborato-
ies. The authors conclude: “We recommend that a com-
rehensive prophylactic protocol needs to be incorporated
nto practice to prevent contrast-induced AKI, incorporat-
ng both NaHCO3 and NAC.” The precedent for a clear-
ut algorithm for care to improve outcomes has been
stablished for interventional cardiology most notably with
espect to primary percutaneous coronary intervention for
T-segment elevation myocardial infarction. Are we now
eady to bring that same kind of clarity to an algorithm to
revent contrast-induced AKI?
here Consensus Rests
he need for ongoing meta-analyses of therapies to prevent
ontrast-induced AKI might be inexorably linked with a
eeling that no single trial provides a clear path. Although it is
rue that this field lacks a single mega-trial on which an
lgorithm can be based, there are real insights over the past 2
ecades that could be adhered to in clinical practice. First, there
re agents that simply do not work: calcium channel blockers,
opamine, mannitol, furosemide, and intravenous fenoldopam.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the University of Vermont College of Medicine, Burlington, Vermont. Dr.i
auerman has served as consultant to and on the advisory boards for Abbott Vascular,
he Medicine Company, and Bristol-Myers Squibb.n contrast, hydration clearly does work, and all patients at risk
or AKI should undergo volume expansion (3,5).
What is the optimum method of volume expansion:
aHCO3 for 7 h or normal saline for a minimum of 12 h? The
urrent meta-analysis might help us with this particular ques-
ion. Although the report focuses conclusions on “combination
rophylaxis,” it is possible this report might fall into the simpler
ategory of “bicarb is better” (6,7). There are 10 trials included
n the current meta-analysis, with a total of 21 treatment
egimens being compared. Of these 21 treatment regimens, all
1 include some form of NAC. Conversely, 10 trials include
aHCO3, whereas 11 trials include intravenous hydration
ith normal saline. Thus, hydration method is the only true
ariable. Elementary school math suggests that the meta-
nalysis might be presenting the following equation for the rate
f contrast-induced AKI:
Bicarbonate  NAC  normal saline  NAC
Subtract NAC from both sides of the equation
Bicarbonate  normal saline
This becomes fuzzy math only if we assume that a back-
round of NAC is differentially required to potentiate the
enefits of NaHCO3 as opposed to normal saline. Because
here is no evidence to support this concept to date, it seems
ore likely that the current meta-analysis extends the conclu-
ions of prior meta-analyses, suggesting that NaHCO3 is the
urrent best regimen for volume expansion (6–8). Although
here are contradictory trials with respect to bicarbonate supe-
iority (9), the clinician might be comforted by the following
ractical points: 1) even when clinical trials have failed to show
uperiority of NaHCO3, they have yet to show evidence of any
arm; 2) it is much easier to give 1 h of NaHCO3 before
rocedure plus 6 h of post-procedure NaHCO3 than any of the
egimens with normal saline that require 12 to 24 h of infusion;
) replacing normal saline as the volume expander of choice has
o cost implications to your institution; and 4) advocates of
aHCO3 for AKI prophylaxis are not financially motivated—
here are no industry ties related to prophylactic salt adminis-
ration.
here Controversy Remains
re the authors correct that NAC should be a mandatory
art of all algorithms for AKI prophylaxis? A missing arm of
his meta-analysis is needed to provide more convincing
vidence—the arm with NaHCO3 alone versus NaHCO3
lus NAC. NAC is a potent antioxidant with real effects on
yocardial salvage and renal cell injury in our porcine
odels (10). But, the results of individual trials and meta-
nalyses of NAC in human studies of AKI have been very
ixed. At least 9 meta-analyses of NAC benefit have been
ublished to date, and the results of these meta-analyses are
nconsistent with respect to a clear benefit of NAC (3,4,11).
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1126n contrast, almost all analysis of NAC is unified with
espect to heterogeneity: no one knows the optimum dose or
oute of administration—oral (12), intravenous (13), or
ntracoronary (10)—and thus the grouped NAC trials are
ifficult to analyze (14).
There are practical aspects of NAC administration that
ight help inform the creation of an algorithm. First, NAC
as not been associated with any clear harm: thus, erring on
he side of NAC use would not be expected to worsen
utcomes. Second, NAC also has no real side effects other
han the awful taste of the oral formulation. Third, the most
ommon dose used is 600 mg orally twice daily the day
efore and the day of the procedure: for outpatients under-
oing elective cardiovascular procedures, this requires a
eparate trip to the pharmacy to obtain a bad-tasting
edication. For inpatients, the ability to administer any
rug over 24 h before invasive procedures is limited by the
rgency of the procedure. Although some studies have
ttempted to overcome this barrier with intravenous (13) or
bbreviated regimens of NAC (15), the results of these trials
like all other trials of NAC) have been conflicting (5).
hus, unlike the bicarbonate versus saline comparison, the
AC versus placebo comparison unfortunately rests firmly
t equipoise and uncertainty.
n Algorithm for Care
he lack of certainty regarding NAC does not negate the
mportant observations of the current meta-analysis or the
ignificant contributions of investigators who have high-
Figure 1. A Sample Algorithm to Address Acute Kidney Injury in Cardiovasc
CHF  congestive heart failure; GFR  glomerular ﬁltration rate; NPO  nothiighted the need to prevent AKI. Rather, the consistency of cndings with respect to: 1) AKI incidence, predictors, and
utcomes; and 2) volume expansion, particularly with
aHCO3, as a meaningful prophylaxis regimen brings
otential for initiation of a uniform algorithm for care. In
uly 2007, we anticipated the authors’ current recommen-
ation: “We encourage institutions to form a multidisci-
linary team . . . to work together to develop evidence-based
enchmarks for high-quality care and standardize their
rophylactic strategies in preventing contrast-induced
KI.” Through meetings with Dr. Richard Solomon, our
hief of Nephrology, we created a “best practices” algo-
ithm to prevent AKI and made this a single, universal
pproach used by every attending physician in our cardio-
ascular catheterization laboratory (Fig. 1).
What did we do in 2008 when a new trial was published
uggesting that “bicarbonate is not actually better” (9)?
ather than change the algorithm, we looked at 2 factors: 1)
id the trial show any negative correlates of continuing our
urrent practice (no)?; and 2) did we expect better compli-
nce by potentially switching between equivalent regimens
n a yearly basis (no)? Thus, our practice continues what the
uthors propose in this meta-analysis, with the lack of a firm
ommitment to NAC. Furthermore, AKI prophylaxis algo-
ithms need to incorporate other factors that might contrib-
te to patient dehydration (no more “NPO after midnight”)
r renal injury (stop the nonsteroidal anti-inflammatory
rugs). And, finally, like all successful algorithms, it is a
implified representation of the published data: although
here are many other risk factors for AKI, we sought 100%
ompliance with this regimen with respect to 1 main factor
creatinine clearance) rather than a host of variables (acute
nfarction, heart failure, diabetes) that might create memory
atheterization Laboratories
mouth; NSAIDs  nonsteroidal anti-inﬂammatory drugs.ular Challenge.
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1127Is the University of Vermont approach correct or com-
lete? There is more than 1 correct algorithm for preventing
KI, and the gray areas dictate a reasonable variability in
pproaches. And clearly there is room for ample discussion
egarding choice of contrast agents to reduce the occurrence
f AKI (3). But the current meta-analysis states that it is
ime for all institutions to both measure AKI and institute
ome form of quality improvement program to address AKI
ith an algorithm for prophylaxis. Our experience suggests
hat this is a correct statement. Our incidence of AKI
mong our PCI patients was 4.6% in 2003. By the end of
008, we had achieved our lowest incidence of AKI to
ate—approximately 2.0% (David Malenka and Winthrop
iper from the Northern New England Cardiovascular
tudy Group, personal communication, July 7, 2009). Thus,
he current meta-analysis might not clearly demonstrate the
bsolute requirement for “combination therapy”; however,
he concordance of meta-analyses on volume expansion
rings to the forefront a new ST-segment elevation myo-
ardial infarction-like area for quality improvement: the
otential to create a uniform institutional algorithm for care
f patients at risk of AKI.
eprint requests and correspondence: Dr. Harold L. Dauerman,
ardiac Unit, McClure 1, Fletcher Allen Health Care, University
f Vermont, 111 Colchester Avenue, Burlington, Vermont 05401.
-mail: harold.dauerman@vtmednet.org.
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